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Abstract We proposed to identify the efficacy of an
epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor (TKI) using whole brain radiotherapy (WBRT)/
stereotactic radiosurgery (SRS)/surgery in brain metastases
from patients with non-small cell lung cancer (NSCLC)
and clarify the association between treatment outcome and
EGFR gene mutation status. A total of 282 patients with
NSCLC brain metastases who underwent WBRT/SRS/
surgery alone or in combination with TKI were enrolled in
our study from 2003–2013. Amplification mutation
refractory system technology was used to determine the
EGFR mutation status in 109 tissue samples. EGFR
mutation detection was performed in 109 patients with
tumor tissues. The EGFR positive rate was 50 % (55/109),
including 26 exon 19 deletions and 24 L858R mutations.
The median follow-up time was 28 months. The median
overall survival, median progression-free survival of
intracranial disease, and median progression-free survival
of extracranial disease was significantly longer for patients
with TKI treatment (31.9 vs 17.0 months, P \ 0.0001; 19.8
vs 12.0 months, P \ 0.0001; and 19.6 vs 12.3 months,
P \ 0.0001; respectively). In subgroup analysis within the
TKI group, patients harboring EGFR mutations had better
extracranial disease control (20.4 vs 14.1 months,
P = 0.032). Administration of TKI agents with conven-
tional therapy compared with conventional therapy alone
might be beneficial for overall survival, progression-free
survival of intracranial disease and progression-free sur-
vival of extracranial disease in patients with brain metas-
tases from NSCLC independent of EGFR mutations.
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Introduction
Non-small cell lung cancer (NSCLC) accounts for
approximately 80 % of all lung cancers, in which brain
metastases (BMs) occur in 20–40 % of all NSCLC cases
and represent a major pattern of treatment failure and cause
of mortality [1, 2]. Whole brain radiotherapy (WBRT) has
been considered as a standard therapy for patients with
BMs and leads to an overall survival (OS) ranging from 3
to 6 months [3, 4]. Although the standard management has
been optimized over time with the development of ste-
reotactic radiosurgery (SRS) combined with systemic
chemotherapy and more accurate patient selection for
appropriate treatment options now depends on a better
definition of prognostic factors, outcomes of BM from
NSCLC remain poor, with a short median survival time of
7–8 months [5].
Tyrosine kinase inhibitors (TKIs) of the epidermal
growth factor receptor (EGFR) have been successfully
employed in NSCLC based on the identification of EGFR
gene mutations. Advances in understanding the molecular
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pathways that mediate brain colonization have led to a new
interest and alternative to traditional therapy in clinical
investigations in BMs from NSCLC [1, 6–9]. EGFR
mutation status has been reported to be associated not only
with improved survival for patients with BMs [10], but also
with the response rate of WBRT [9]. More recently, TKIs
have demonstrated a distinct therapeutic potential against
BMs from NSCLC and have improved the median OS to
9–13.5 months [11–14]. Furthermore, a few studies
reported an improved median OS of 13–23.4 months for
BMs patients using TKIs concomitant or pretreated with
WBRT [11, 15, 16].
Thus far, several studies have demonstrated the effi-
cacy of using TKIs in patients with BMs from NSCLC.
However, few studies have been published that discuss
the relationship between EGFR gene mutation status and
response rate for TKI administration simultaneously with
WBRT/SRS/surgery in patients with BMs. In our study,
we retrospectively reviewed 282 patients with BMs from
NSCLC who received WBRT/SRS/surgery with or with-
out TKI and detected the gene mutation status of tumor
tissues from 109 patients. We proposed to investigate the
efficacy of TKI in combination with traditional therapy
and explore the relationship between EGFR gene muta-




We retrospectively retrieved the data of 530 patients with
brain metastasis from NSCLC treated in Sun Yat-sen
University Cancer Center from 2003 to 2013. This study
was approved for the use of tumor samples and patients’
clinical history by the Institutional Review Board. The
main eligibility criteria were pathologically confirmed
NSCLC and medical image measurable brain metastases.
Consequently, a total of 282 patients treated with con-
ventional therapy alone or in combination with TKI were
included in this study. Conventional therapy included
WBRT, SRS, or surgery (S), or a combination of these. All
medical records were reviewed for age, gender, symptoms,
physical examination, laboratory examination, imaging,
pathological diagnosis, stage, biomarker detection, chest
computed tomography, magnetic resonance imaging of the
brain, modality of treatment, site and number of BMs, time
to disease progression, time to death, and last follow-up
date. Patients were treated according to our institute’s
policy. All patients were grouped into TKI plus conven-




Among all 282 patients, 109 (39 %) had adequate tumor
tissue or lymph node biopsy samples for molecular analysis.
The samples were formalin-fixed and paraffin-embedded
(FFPE). All tumor specimens went through pathological
evaluation to confirm the diagnosis of NSCLC and the per-
centage of tumor cells. As the analytical sensitivity of the
ARMS method is approximately 1 %, at least 1 % of tumor
cells were required for the following mutation detection.
DNA extraction and quality check
The QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden,
Germany) was used for DNA extraction from tumor tissue
samples following the instructions in the user manual.
Extracted DNA samples were quantified by the real time
quantitative PCR method using a commercial Taqman
assay for the RNase P gene (Life Technologies, USA). The
concentration of each DNA sample was normalized to
0.4 ng/lL whenever possible. When the DNA concentra-
tion was lower than 0.4 ng/lL, the original DNA stock
solution was applied.
EGFR mutation detection by the ARMS method
The EGFR Mutation Detection Kit (Amoy Diagnostics,
Xiamen, China), which is based on the ARMS (amplifi-
cation mutation refractory system) technology, was used to
detect the 29 most common types of EGFR mutations and
the T790 M mutation in lung cancer. All experiments were
performed following the user manual. Briefly, 4.7 lL DNA
was added to 35.3 lL PCR master mix, which contains
PCR primers, fluorescent probes, PCR buffer, and Taq
DNA polymerase. PCR thermal cycling was set as: 95 C
for 5 min, followed by 15 cycles of 95 C for 25 s, 64 C
for 20 s, 72 C for 20 s, and then 31 cycles of 93 C for
25 s, 60 C for 35 s, 72 C for 20 s. Fluorescent signals
were collected from the FAM and HEX channels. The
results were analyzed according to the instructions from the
user manual.
Statistical methods
OS was calculated from the date of diagnosis to the date of
last follow-up or death from any cause. Progression-free
survival for intracranial disease (PFSI) was calculated from
the date of diagnosis to the time to CNS-progression.
Progression-free survival for extracranial disease (PFSE)
was calculated from the date of diagnosis to the time to
extracranial disease progression. Survival curves were
424 J Neurooncol (2014) 120:423–430
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constructed using the Kaplan–Meier method and differ-
ences were considered significant if the p value was less
than 0.05 (two-tailed log-rank test). Multivariate analysis
(Cox-model) was used to determine the independent
prognostic factors. All prognostic factors identified in the
univariate analyses with P values \0.20 were included in
the multivariate analyses.
Results
Patient and treatment characteristics are presented in
Table 1.
The median age was 65 years (range 30–78 years).
There were 180 males and 102 females included in the
study. Adenocarcinoma was the dominant pathological
subtype, occurring in 87 % of patients. Patients with
intracranial symptoms were found more in the non-TKI
group (36 %) than in the TKI group (13 %) (P = 1.21E-
06). The non-TKI group had more patients with C3 BM
numbers than the TKI group (P = 0.027).
Radiotherapy was performed on a majority of patients
(70 %), in which WBRT accounted for 54 % and SRS for
16 %. Synchronous distant metastases were observed in 55
patients from the TKI group compared with 92 patients
from the non-TKI group.
EGFR mutation analysis was performed in 109 (38 %)
patients with tissue samples. In the patients where EGFR
detection was performed, the rate of EGFR positivity was
26 % in the TKI group compared with 24 % in the non-
TKI group. Among the 55 (55/109) patients with EGFR
mutations, 26 were exon 19 deletions, 24 had L858R
mutations, and 5 harbored mutations in exon 19 and L858R
simultaneously. In addition, none of the tested samples
were positive for the T790 M mutation. Patients having
EGFR L858R point mutations had a longer but non-sig-
nificant median overall survival (MOS), median progres-
sion-free survival for intracranial disease (MPFSI) and
median progression-free survival for extracranial disease
(MPFSE) compared to patients with exon 19 deletions
(Table 2).
With a median follow-up of 28 months (range,
22–34 months), 16 % (45) of patients were alive without
evidence of disease progression, 17 % (48) were alive with
disease, and 67 % (189) patients were dead due to disease
progression. Overall, MOS, MPFSI, and MPFSE in the TKI
group were 31.9 (95 % CI: 27.8–35.6), 19.8 (95 %CI:
16.8–22.8), and 19.6 (95 %CI: 16.4–22.8) months com-
pared with 17.0 (95 % CI: 14.5–19.5) (P \ 0.0001), 12.0
(95 %CI: 10.4–13.6) (P \ 0.0001), and 12.3 (95 % CI:
10.4–14.2) (P \ 0.0001) months in the non-TKI group,
respectively (Fig. 1). A better outcome of MOS, MPFSI
and MPFSE was observed in the TKI group compared to
the non-TKI group independent from gene mutation status
(Table 2).
Using univariate analyses, statistically significant factors
favorably influencing MOS in the TKI group were as fol-
lows: patients with no extracranial disease, N0 stage,
adverse drug reaction, and TKI taking time over 8 months.
In the non-TKI group, less than 3 BMs number, less than
3 cm in maximum diameter of a BM lesion, no extracranial
disease, T stage equal to or less than 1, and N0 were
favorable factors influencing MOS (Table 3). For MPFSI,
no significant factors were found in the TKI group, except
for patients taking TKI over 8 months. However, patients
with less than 3 cm in maximum diameter of BMs lesions
Table 1 Clinical characteristic for patients
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or in N0 staging had better outcome in the non-TKI group
(Table 3). For MPFSE, patients with EGFR mutations had
a longer time to extracranial disease progression of
20.4 months compared with 14.1 months in EGFR
negative patients (P = 0.032) in the TKI group. No dif-
ference could be found between EGFR positive and neg-
ative patients in the non-TKI group. The following
parameters were in favor of MPFSE in the TKI group: BMs
Table 2 EGFR mutation status in association with TKI treatment
EGFR mutation MOS MPFSI MPFSE
TKI group Non-TKI P value TKI Non-TKI P value TKI Non-TKI P value
Positive 30.9 11.2 \0.0001 17.9 9.6 0.0004 16.3 9.0 \0.0001
Del-19 23.6 P 10.9 P 18.5 P 5.7 P 16.1 P 8.0 P
L858R 32.8 0.55 13.7 0.49 16.3 0.89 10.9 0.75 17.0 0.67 9.3 0.41
Negative 28.4 14.7 \0.0001 18.6 11.4 0.0032 12.7 10.4 0.0098
MOS median overall survival, MPFSI median progression-free survival of intracranial disease, MPFSE median progression-free survival of
extracranial disease
Fig. 1 Survival curves in TKI and non-TKI groups, respectively. a Overall survival; b Progression-free survival of intracranial disease;
c Progression-free survival of extracranial disease
Table 3 Survival analysis (Log-rank test) according to clinical-pathological factors in NSCLC Patients with BM
Variable TKI group (N = 104) Non-TKI group (N = 178)
MOS MPFSI MPFSE MOS MPFSI MPFSE
EGFR test (positive vs. negative) NS NS S (P = 0.032) NS NS NS
Age (\54years vs. C54years) NS NS S (P = 0.014) NS NS NS
Gender (female vs. male) NS NS NS NS NS NS
Smoking status (ever vs. never) NS NS NS NS NS NS
Histological type NS NS NS NS NS NS
Number of BM (cut off 3) NS NS NS S (P = 0.021) NS NS
Size of BM (cut off 3 cm) NS NS NS S (P = 0.012) S (P = 0.025) S (P = 0.032)
Treatment option (WBRT vs. S/SRS) NS NS S (P = 0.011) NS NS NS
Extracranial lesions (yes vs. no) S (P = 0.0002) NS S (P = 0.013) S (P = 0.003) NS NS
Intracranial symptoms (yes vs. no) NS NS NS NS NS NS
T staging (T B 1 vs. T [ 1) NS NS S (P = 0.029) S (P = 0.005) NS S (P = 0.007)
N staging (N0 vs N1 ? 2 ? 3) S (P = 0.0003) NS S (P = 0.0005) S (P = 0.0005) S (P = 0.037) NS
Adverse drug reaction (yes vs. no) S (P = 0.0002) NS S (P = 0.0075)
TKI taking time (cut off 8 ms) S (P \ 0.0001) S (P = 0.0006) S (P = 0.0013)
MOS median overall survival, MPFSI median progression-free survival of intracranial disease, MPFSE median progression-free survival of
extracranial disease, NS no significant, S significant
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patients who underwent S/SRS, no extracranial disease, T
stage B1, N0, adverse drug reaction, taking TKI more than
8 months, and age \54 (Table 3).
After multivariate analysis, the remaining common
independent prognostic factor for OS, PFSI and PFSE was
taking TKI over 8 months in the TKI group. In addition to
this, no extracranial disease was also an independent factor
for OS. Patients treated with S/SRS or in N0 stage favored
PFSE in the TKI group. In the non-TKI group, never
smoking, BMs number \3, BMs lesion size \3 cm, no
extracranial disease and N0 were independent factors for
OS (Table 4).
Discussion
The prognosis of patients with BMs from NSCLC remains
poor even with optimized multi-modality treatments with
WBRT plus SRS, surgery or chemotherapy. WBRT has
been considered as a standard treatment option in patients
with BMs from NSCLC [3, 4], but it causes neurotoxicity
which leads to leukodystrophy. SRS or surgery could be an
alternative option, but only for a small subset of patients
with solid or oligo-lesions. However, either intracranial or
extracranial disease advances rapidly even when BMs are
well controlled with conventional therapy and become
main patterns of treatment failure in this setting. On the
other hand, it has been demonstrated previously that sys-
temic chemotherapy is generally inactive against BMs [17].
This chemotherapeutic drug resistance has been shown to
be caused by decreased penetration into the parenchyma
because of the blood–brain barrier (BBB) [17]. However,
this hypothesis has been challenged by both animal and
clinical studies. These recent studies have revealed that the
BBB is already leaky in BMs with tumors [0.25 mm in
diameter, and BMs tumors are as sensitive to
chemotherapeutic drugs as extracranial tumors in NSCLC
[17]. Thus, the BBB no longer plays an important role in
the multidrug resistance of BM, and the chemosensitivity
in metastasis lesions seems to primarily dominate the
responsiveness of chemotherapy [17].
Since TKI therapy has demonstrated a high response
rate for EGFR mutation carriers in NSCLC, many previous
studies intended to improve the survival of BMs patients
from NSCLC using targeted agents in addition to con-
ventional therapy [11, 12, 14, 17–20]. In early studies of
molecularly targeted therapy in BMs from NSCLC,
monotherapy of TKI agents (Gefitinib or Erlotinib) showed
a distinct therapeutic potential against BMs [11, 21].
Cappuzzo et al. [21] were the first to report the possible
activity of TKIs on BMs from NSCLC in a compassionate
use program. Previously, an immunohistochemical and
morphometric analysis in an experimental BMs model in
mice identified various growth factors as positive regula-
tors of angiogenesis [22, 23]. This discovery of molecules
involved in angiogenesis promised new targeted agents in
anticancer therapy for patients with BMs from NSCLC.
Then, a prospective study [11] of Gefitinib on BMs from
NSCLC reported that the response rate (RR) of TKI use in
BMs patients was 10 %, with a median duration of
response of 13.5 months and MOS of 5 months. Another
review of 15 BMs from NSCLC reported that the RR of
TKI use in BMs was 60 %, which was similar to the pri-
mary lung tumor, with a median duration of response of
8.7 months [17]. The increased RR is most likely attributed
to previous radiation therapy.
In our study, a total of 109 cases (39 %) with primary
tumor tissues or lymph node samples underwent EGFR
mutation detection. Among patients with sample detection,
46 % (50) were in the TKI group and 54 % (59) were in the
non-TKI group. The EGFR mutation rate was 50 %, which
was similar to our published data [24]. We showed a
Table 4 Results of multivariate survival analyses for TKI group according to the cox regression model
Variables TKI group Non-TKI group
OS PFSI PFSE OS PFSI PFSE
RR P value RR P value RR P value RR P value RR P value RR P value
Extracranial lesions (yes/no) 0.62 0.0007 – – – – 0.80 0.0037 – – – –
TKI taking time (cut off 8 ms) 0.58 0.0001 0.41 0.0008 0.73 0.0106 – – – – – –
Treatment option (WBRT vs. S/SRS) – – – – 0.69 0.0103 – – – – – –
Smoking status (never) – – – – – – 0.82 0.0127 – – – –
BM number (\3) – – – – – – 0.84 0.0247 – – – –
BM size (\3 cm) – – – – – – 0.79 0.0120 – – – –
T staging – – – – – – – – – – 0.81 0.0087
N staging – – – – 0.76 0.0281 0.65 0.0000 0.78 0.0011 0.79 0.0020
OS overall survival, PFSI progression-free survival of intracranial disease, PFSE progression-free survival of extracranial disease
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significant improved outcome for patients in the TKI group
with MOS, MPFSI and MPFSE of 31.9, 19.8 and
19.6 months, respectively, compared to 17.0, 12.0 and
12.3 months in the non-TKI group. TKI agents were
administered as first line treatment to the patients followed
by WBRT/SRS/S, or in combination with chemotherapy. In
our subset analysis regarding the EGFR mutation status in
association with the efficacy of TKI agents, we found that
TKI treatment was beneficial for BMs patients in regards to
MOS, MPFSI and PFSE independent from the EGFR
mutation status. In a previous prospective randomized
study undertaken in Asian patients, the Iressa Pan-Asia
study (IPASS) [25] demonstrated the superiority of Gefi-
tinib as a first line treatment compared to chemotherapy for
EGFR positive patients with respect to PFS. Similarly,
WJTOG 3405, NEJ 002, OPTIMAL and Hirsch FR’s
studies [26–29] confirmed the improved outcome of PFS of
up to 18.2 months for Gefinitib or Erlotinib treatment
compared to standard chemotherapy in patients with EGFR
mutations. Furthermore, the EURTAC [30] study addres-
sed the same findings of TKI use as a first line treatment in
advanced NSCLC harboring EGFR mutant tumors among a
non-Asian population. Our analysis showed a similar out-
come for TKIs administered as a first line treatment fol-
lowed with conventional therapy in BMs patients. Also, the
subgroup analysis within the TKI group showed a superi-
ority of PFSE in patients with EGFR positive mutations.
However, a non-significant but potentially better outcome
of OS and PFSI was observed in EGFR positive patients.
Our findings suggested that TKI administration had a
superior effect as a first line treatment on OS and PFS for
patients with BMs from NSCLC, but the EGFR mutation
status made no difference for OS and PFSI. This might be
due to the interfering efficacy of following treatment with
WBRT/S/SRS or chemotherapy, which also contributes to
the response rate of either the primary tumor or metastatic
lesions, particularly those with pathologic heterogeneity.
On the other hand, the prolonged survival of PFSE indi-
cated that there was increased efficacy of TKI agents on
extracranial disease control for patients with EGFR posi-
tive mutations. This implied that the initial advantage of
TKI treatment to patients with EGFR mutation suppresses
the interference of chemotherapy.
So far, published data have shown a range of 133 days
to 23.4 months for MOS and 141 days to 10.6 months for
MPFS in BMs patients with concomitant treatment of TKI
and WBRT [15, 16, 31, 32]. Our data showed a much
longer MOS, MPFSI and MPFSE than previous studies,
most likely due to delivering the TKI as a first line therapy.
However, recently published data from RTOG 0320 [31]
failed to demonstrate the advantage of Erlotinib concomi-
tantly administered with WBRT plus SRS in NSCLC
patients with 1–3 brain metastases. This result was most
likely due to the relatively small sample size and ineffec-
tiveness of Erlotinib as doublet chemotherapy for systemic
disease control [31]. Our results were quite different from
the RTOG 0320 trial. The possible explanations for the
differences in survival might be the following: (1) Neuro-
toxicity increased with the concomitant delivery of TKI
with WBRT plus SRS. (2) Chemotherapy was delivered in
sequence to patients in a combination with TKI in our
study. The sequential administration of TKI and chemo-
therapy might enhance the control of systemic disease by
either drug due to the potential anticancer ability against
tumor heterogenicity, which was reflected in prolonged OS
and PFSE. Published data from the FAST-ACT II trial [33]
also showed a significant improvement in PFS with
sequential administration of erlotinib following gemcita-
bine/platinum chemotherapy.
In conclusion, administration of TKI agents with con-
ventional therapy might have a beneficial effect on MOS,
MPFSI and MPFSE for patients with BMs from NSCLC
compared to conventional therapy alone. Patients harboring
EGFR mutations not only had significant improvement in
PFSE with TKI plus conventional treatment compared to
EGFR negative patients, but also had a non-significantly
better outcome of OS and PFSI. This treatment strategy
warrants further investigation in a prospective study.
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